Newsletter · · Ashutosh Agarwal

Providers Turn on the Payers as CVS and UNH Get Priced for a Fight - Managed Care Under Pressure - Week of September 19, 2026

Managed Care Under Pressure for the week of September 13 to September 19, 2026: CVS drew 340B lawsuits from safety-net hospitals while launching Cigna Health Works, UnitedHealth faces a September 30 New York-Presbyterian out-of-network deadline and sold a WellMed stake to TPG, a Health Affairs analysis put Medicaid state-directed-payment cuts at $51 to $52 billion a year across 36 states, a Cain Brothers banker argued the Medicaid rate lookback is catching up to a sicker population, and CMS weighed a moratorium on new ACA agents.

Managed Care Under Pressure

Week of September 19, 2026: Providers Turn on the Payers as CVS and UNH Get Priced for a Fight

TL;DR

  • The Wall Street voice came back, and it wasn't kind. After weeks of policy podcasts doing all the talking, a market-focused show this week put actual price tags on the group and framed CVS Health (CVS) and UnitedHealth (UNH) as "cheap for a reason": both spent the week fighting their own hospitals. CVS is being sued by safety-net providers over withheld 340B drug payments; UNH faces a September 30 deadline before New York-Presbyterian, the biggest hospital system in its biggest market, walks out of network. One caveat worth stating up front: that show is AI-generated market commentary, not a human hedge-fund analyst, so treat its specific numbers as its own house figures.
  • The Medicaid funding cut got a second, bigger price tag, and a rare optimistic footnote. A new Health Affairs analysis discussed this week pegs the state-directed-payment cut at roughly $51–52 billion a year across 36 states (out of about $106 billion in above-Medicare payments). But an investment bank's take added a wrinkle almost nobody is saying out loud: the Medicaid rate formula runs on a two-to-three-year lookback, so the recent squeeze partly reflects stale data, and as newer, sicker-population data works its way in, rates should start catching up.
  • Still policy-heavy, but broader than usual. Coverage spanned six different channels this cycle: a market show, an investment bank, a hospital-advisory firm, a pharmacy-benefit operator, an insurance-broker show, and a safety-net health-system CEO.

What's New

1. The investor lens returned, and it framed CVS and UNH as "the honest version of cheap." On Telltales, a markets recap podcast that is openly AI-generated ("both voices you're hearing are AI-generated," role: market commentary/pundit, not a human analyst), the hosts walked through four healthcare names and split managed care off as the one corner of the sector "where the price actually reflects the fight." Two concrete, checkable developments drove it:

  • CVS is "getting sued by more hospitals," with safety-net providers alleging the company withheld payments tied to 340B, the federal program that requires drugmakers to sell discounted drugs to hospitals serving low-income patients. In the same seven-day window, CVS launched a joint product with Cigna (CI) called Cigna Health Works, routing Cigna-administered benefits into CVS pharmacies and MinuteClinics: "sued by its providers and partnered with a rival insurer inside seven days."
  • UNH faces a hard date: New York-Presbyterian, described as the largest hospital system in New York, "goes out of network for most UnitedHealthcare commercial plans on September 30th unless the two sides reach a deal." Separately, UnitedHealth "sold an ownership interest in its Florida WellMed clinics to the private equity firm TPG," "selling the clinics on one coast, fighting over the hospitals on the other."

The show then put its own valuation frame on it: by its internal "cash flow memo" numbers, CVS trades at about 15 times free cash flow (on roughly $12 billion of it) and UnitedHealth at about 22 times, "the lowest multiples on anything that gets a beat tonight." Its verdict: "When your providers are suing you, and the largest hospital system in your biggest market is weeks from walking, the market discounts the cash flow instead of extrapolating it. That's the honest version of cheap... What settles it is the network contract, not the multiple." Telltales, "Weekend Update - W2637" (2026-09-14)

Why it matters: For the first time in weeks, a podcast took a ticker-level, valuation-aware view of the group. The facts it surfaced are the actionable part: a September 30 New York-Presbyterian contract cliff for UNH's commercial book, fresh 340B litigation against CVS, a new CVS-Cigna commercial distribution tie-up, and a UNH clinic divestiture to TPG. The multiples are the show's own house figures, not independently verified here, so use them as a sentiment read rather than a source of truth.

2. The Medicaid state-directed-payment cut got a second, larger estimate, plus the site-of-care shift nobody is watching. On Achieving Health, the weekly "Washington Watch" from advisory firm Forvis Mazars, hosts Chad Mulvaney and Sean Stack (role: healthcare-advisory experts) walked through a new Health Affairs analysis of the same policy we covered last week: the H.R.1 / One Big Beautiful Bill Act cap on "state-directed payments," or SDPs (the mechanism by which a state directs its Medicaid managed-care plans to pay hospitals and doctors above the low baseline Medicaid rate). Their figures: across 39 states, SDPs exceeding Medicare rates averaged about $106 billion a year, roughly 12.5% of total Medicaid spending, and cutting the highest-paying ones down to Medicare-equivalent levels "could require approximately $51, almost $52 billion in annual payment reductions across the 36 states that were studied." Crucially, they stressed the study was done "before the CMS proposed rule expanded the policy beyond the statutory requirements, meaning the actual impact will be significantly greater." Most exposed states named: Nebraska and South Carolina; provider-tax restrictions add pressure in Arizona, Michigan, Rhode Island and Virginia. In their own 2026 client survey, "half of executives identified state-directed payment changes as their greatest OB-3-related concern, and almost half anticipate margin reductions of at least 3%."

They then flagged a second, under-discussed lever: CMS's proposed 2027 Outpatient Prospective Payment System (OPPS) rule would remove 637 procedures from the inpatient-only list and add 618 to the ambulatory-surgery-center (ASC) list, "more than double last year's 285." Stack's framing: "2026 was an inpatient to hospital-outpatient discussion, but 2027 is an inpatient to ASC discussion." One payer-favorable nugget buried in the survey: 28% of provider executives said Medicare Advantage plans have successfully used hospital price-transparency data to negotiate lower rates, versus only 22% of providers who used the same data to push rates up. Achieving Health, "Washington Watch: Medicaid Cut Pressures, Employer Health Benefit Strategies, Site-of-Care Shifts" (2026-09-16)

Why it matters: This is a second, independent estimate that corroborates and enlarges last week's Mathematica paper ($52 billion, 17 states). Most of the SDP hit lands on hospitals, but it shrinks the Medicaid dollar pool that CNC, MOH, ELV and UNH's Medicaid books swim in. The site-of-care shift is a slower burn: as high-margin surgeries migrate out of hospitals into cheaper ASC settings, and commercial payers follow Medicare's lead, it pressures hospital economics further and hands managed-care plans a new tool to steer volume to lower-cost sites.

3. An investment bank explained why Medicaid margins broke, and hinted the worst of the rate lag may be passing. On House Calls, from Cain Brothers (a division of KeyBanc Capital Markets), managing directors Dave Johnson and Mike Elizondo (role: healthcare investment bankers, the closest thing to a finance-desk voice this week) gave the cleanest explanation yet of the Medicaid margin squeeze. During the pandemic, states stopped checking eligibility and let the rolls balloon. Many of those enrollees were what Elizondo called "zero utilizers", people who kept coverage but didn't use it, while "the payers may have also been receiving capitation" for them. Those healthy members effectively subsidized the sick ones. Now they are being purged, "so you've got a reduction in the monies coming in to take care of the population that's left," which is sicker: "you've got this acuity mismatch." That, he said, "is the biggest thing that's happened."

The forward-looking part: Medicaid rates are set on a "two-year, three-year lookback... with a population today that is fundamentally different. We're getting through some of that now, so more of that lookback is taking in more time that represents the existing population today." In plain terms, the rate formula has been paying on stale, healthier-population data, and as current sicker-population data feeds in, rates should better reflect real acuity. Elizondo also noted payers "were doing really well not too long ago in this program" and arguably should have built more reserves. House Calls, "Quick Hits: Moving Forward with Medicaid" (2026-09-16)

Why it matters: This is the mechanism behind everything CNC, MOH and ELV have been complaining about, and the first constructive note in a while. If the rate-setting lookback is finally catching up to the sicker post-redetermination population, 2027 state rate updates could start to close the gap between what plans are paid and what their members actually cost. That is the core bull crux for the Medicaid names heading into next year.

4. A quiet 2027 quality-bonus change: a Medicare Star measure is about to start counting again. On The Astonishing Healthcare Podcast (from pharmacy-benefit manager Judi Health / Judi Rx), pharmacists Jay Tran (VP of Clinical and Client Operations) and Angela Kalantarova (Senior Clinical Program Manager), role: PBM operators, flagged that the Medication Therapy Management (MTM) measure moves from "display" status back to a counted Star Ratings measure in 2027. Star Ratings drive the quality-bonus payments that fund Medicare Advantage, so a measure "counting" again matters. CMS expanded MTM eligibility roughly two years ago, lowering the annual drug-cost threshold from $5,300 to $1,200 and adding "core" disease states like Alzheimer's, bone disease, arthritis and mental health, which the hosts said should drive "a three-to-four-fold increase" in eligible members industry-wide (Judi Health's own book already saw a two-times jump from 2025 to 2026). They also noted the Medicare Plan Finder measure is being removed for 2027, and a new opioid-duration measure (IOPLD) may become a Star measure as soon as 2028. The Astonishing Healthcare Podcast, "AH117 - Star Ratings Changes in 2027 Plans Can't Ignore" (2026-09-18)

Why it matters: Star Ratings are money: a plan that slips below 4 stars loses its quality bonus, which is why UNH's and CVS/Aetna's Star-ratings litigation has been such a live issue. A newly-counted measure with three-to-four times as many eligible members is a fresh operational bar plans must clear in 2027 to protect those bonus dollars. It is technical, but it is exactly the kind of thing that shows up in a Star cut a year later.

5. The ACA exchange story added an enforcement chapter: fraud data and a possible agent freeze. On The Seven Figures Or Bust Podcast (an insurance-broker show, role: agents/distribution), the hosts dug into CMS's consideration of a moratorium on new Affordable Care Act (ACA) agents and the fraud data behind it. They cited a Fox News interview in which CMS Administrator Dr. Mehmet Oz said roughly three million people in Florida were enrolled in ACA coverage claiming a specific low-income category, versus only about 636,000 actually eligible, "nearly five people enrolled for every one potentially eligible person." They referenced 134,000 complaints from people who said they were signed up without their knowledge and 74,000 whose plans were changed without consent. One host, a longtime agent, described being at a 2022 industry event where agents were openly "teaching agents to lie about income... just put down zero dollar income on the app." Their worry: a blanket moratorium punishes compliant agents and, with enhanced subsidies now gone, leaves "more people than ever who are just opting out of health insurance in the under-65 market." The Seven Figures Or Bust Podcast, "Episode 271 - Is CMS Placing A Moratorium On New ACA Agents?" (2026-09-14)

Why it matters: Last week the ACA story was about shrinking enrollment and 100%-plus premium jumps as enhanced subsidies expired. This week it gained an enforcement edge: a fraud crackdown and a possible agent freeze on top of the subsidy cliff. Together they point to a smaller, more scrutinized, and adverse-selection-prone marketplace pool, which matters most for CNC (the largest exchange insurer) and, secondarily, ELV, CVS/Aetna and MOH.

The Debate

Bull (the trough is forming; discipline and the rate catch-up pay off into 2027): This week's most constructive point came from a bank, not a bull: if the Medicaid rate formula's two-to-three-year lookback is finally absorbing the sicker post-redetermination population, 2027 state rates should better match real acuity, closing the gap that has crushed CNC, MOH and ELV margins. On the commercial side, hospital-advisory data suggests MA plans are actually winning rate negotiations using price-transparency data (28% of providers said MA plans used it to cut rates, versus 22% of providers who raised them). And the "shrink to fix" discipline we've tracked for weeks continues: UNH's sale of its WellMed clinic stake to TPG is the kind of capital recycling a disciplined operator does. Fewer, better-priced members plus catching-up rates is the recovery path.

Bear (this is a multi-year, government-driven reset, and now the providers are fighting back): The revenue line is being squeezed from every government market at once: Medicaid ($51–52 billion of state-directed-payment cuts across 36 states, with the real number "significantly greater"), the ACA exchanges (subsidy cliff plus a fraud crackdown and possible agent freeze), and Medicare Advantage (a newly-counted Star measure raising the quality-bonus bar). New this week: the providers are now openly at war with the payers, CVS sued over 340B, UNH weeks from losing New York-Presbyterian. Network fights are margin fights, and a market show already marked CVS and UNH down to mid-teens and low-20s free-cash-flow multiples because of it. Shedding members leaves a sicker residual pool (adverse selection), and the political backdrop stays hostile.

The tie-breaker to keep in mind: the one investor-lens podcast this week was AI-generated market commentary, not a human analyst with a book.

Stocks in Play

Fresh, name-specific detail this week landed on CVS and UNH (the provider fights and corporate actions) and, at the sector level, the Medicaid and ACA names. The rest is the standing setup updated for this week's themes.

  • UNH (UnitedHealth): Bull: biggest and most diversified; Optum services cushion; recycling capital (sold WellMed clinic stake to TPG); Medicaid rate lookback may start catching up. Bear: September 30 New York-Presbyterian out-of-network cliff for its commercial book; a market show flagged it at ~22x free cash flow "for a reason"; DOJ MA-coding overhang still live. Next catalyst: whether the New York-Presbyterian contract renews without giving away margin; any DOJ/RADV coding news.
  • CVS (CVS Health / Aetna): Bull: integrated model, Caremark scale, new Cigna Health Works commercial distribution tie-up. Bear: fresh 340B lawsuits from safety-net hospitals; a market show pegged it at ~15x free cash flow, the cheapest "beat" on its board; Aetna exposed to exchange shrinkage. Next catalyst: how the 340B litigation and provider disputes resolve; 2027 benefit design.
  • CI (Cigna): Bull: cleanest of the group on government exposure (little MA), Evernorth growing, and now a distribution partnership with CVS (Cigna Health Works). Bear: Express Scripts remains a prime PBM-reform and employer-carve-out target. Next catalyst: PBM legislation and employer renewals; how the CVS partnership performs.
  • CNC (Centene): Bull: disciplined Medicaid and exchange underwriter; the biggest beneficiary if the Medicaid rate-lookback catch-up thesis is right. Bear: most exposed to this week's two policy themes, the state-directed-payment cut and a shrinking, fraud-scrutinized ACA exchange pool. Next catalyst: 2027 state Medicaid rate updates versus acuity; exchange margin as subsidies lapse.
  • MOH (Molina): Bull: focused Medicaid specialist, most leveraged to any 2027 rate catch-up. Bear: most levered to Medicaid disenrollment and the SDP funding squeeze; smaller, sicker pool risk. Next catalyst: state rate adequacy versus acuity shift.
  • ELV (Elevance): Bull: diversified across MA, Medicaid and exchanges. Bear: Medicaid book exposed to SDP cuts and enrollment declines; exchange erosion. Next catalyst: 2027 Medicaid rate adequacy against a sicker, smaller pool.
  • HUM (Humana): Bull: furthest along "shrink to fix"; MA-heavy, so a 2027 Star-ratings and quality-bonus story more than a Medicaid one. Bear: the newly-counted MTM Star measure raises the 2027 quality bar; still a political target. Next catalyst: 2027 Star Ratings and whether the MA footprint stops shrinking.

Read-Throughs

  • Medicaid / exchange insurers (CNC, MOH, ELV): Two forces pulled in opposite directions this week. Bearish: a second, larger estimate of the state-directed-payment cut ($51–52 billion across 36 states, likely more) plus H.R.1 coverage-loss mechanics that accelerate disenrollment (see below). Bullish: an investment bank's point that the Medicaid rate-setting lookback is finally absorbing the sicker current population, which should push 2027 rates toward real acuity. CNC and MOH carry the most concentrated exposure to both.
  • Medicaid coverage losses have hard dates now. On Becker's Healthcare Podcast, Dr. Erik Mikaitis, CEO of Cook County Health (a large public safety-net system that also runs County Care, Cook County's largest Medicaid plan; role: provider/payer operator) laid out the timeline: enhanced tax subsidies ended in January and Illinois has already seen "over 90,000 people forego their coverage"; as of October 1, certain qualifying immigrants (domestic-violence and trafficking victims, asylum seekers, about 10,000 in Illinois) lose Medicaid eligibility and become uninsurable; and in January, work requirements (80 hours/month) hit Medicaid-expansion adults while their redetermination paperwork doubles from annual to every six months. The awareness gap is stark: a study he cited found 55% of Medicaid enrollees don't know work requirements are coming and 85% don't know redeterminations are doubling, which all but guarantees eligible people fall off the rolls. He cited estimates of ~400,000 Illinois enrollees and 8–10 million nationally losing coverage. Becker's Healthcare Podcast, "Erik Mikaitis on Medicaid Changes and Protecting the Safety Net" (2026-09-14) Read-through: administrative disenrollment (people losing coverage over paperwork, not eligibility) shrinks the Medicaid membership base for CNC, MOH, ELV and UNH, and tends to strip out the healthier, less-engaged members first, worsening the acuity mix.
  • PBMs and Optum-style services arms (Caremark/CVS, Express Scripts/CI, Optum Rx/UNH): The 340B lawsuits against CVS put the pharmacy/services arm directly in a provider fight, and the new CVS-Cigna Health Works product shows the PBMs still chasing commercial distribution even as regulatory pressure builds. The 2027 Star-ratings MTM change is a fresh operational cost for the pharmacy-quality functions inside these plans.
  • Hospitals / providers: They sit on the other side of every trade this week: suing CVS over 340B, threatening to walk from UNH's network, and absorbing the brunt of both the state-directed-payment cut and the site-of-care shift to ASCs. The Forvis Mazars data (700-plus obstetric-unit closures since 2010; Medicaid funding ~41% of U.S. births) is the sharp end of a shrinking Medicaid dollar pool.

What Changed vs Last Week

Last week (week of 2026-09-12) was demand- and funding-side policy: the Medicaid state-directed-payment cut quantified (Mathematica: $52 billion, 17 states), Medicare Advantage forced-disenrollment data plus a Humana CFO quote, and the ACA exchange erosion finally appearing (enrollment down 13%, premiums up 114% for subsidy losers).

This week:

  • Advanced: the investor lens returned. For the first time in weeks a podcast took a ticker-level, valuation-aware view of the group. The catch: it was Telltales, an AI-generated market show, not a human analyst. But the facts it surfaced are new and concrete: CVS 340B hospital lawsuits, the CVS-Cigna Health Works launch, UNH's September 30 New York-Presbyterian out-of-network deadline, and UNH's WellMed clinic-stake sale to TPG.
  • Advanced: the Medicaid cut got a second, larger estimate and a constructive footnote. A different Health Affairs analysis (39 states, ~$106 billion of above-Medicare SDPs, $51–52 billion of cuts across 36 states, "significantly greater" once the CMS rule is finalized) corroborated and enlarged last week's number. And an investment bank added the first genuinely bullish crux in a while: the Medicaid rate-setting lookback may be catching up to the sicker current population, supporting 2027 rates.
  • Advanced: new angles on old themes. The ACA story gained a fraud/enforcement chapter (Dr. Oz's Florida data, a possible CMS agent moratorium). The Medicaid coverage-loss story gained hard dates and awareness-gap data (October 1 immigrant cutoff, January work requirements plus six-month redeterminations, 55%/85% awareness gaps). And 2027 Star Ratings surfaced a newly-counted MTM measure, a quality-bonus wrinkle.
  • Smaller divestiture data point: UNH's WellMed-to-TPG sale is a real, if modest, piece of portfolio reshaping alongside the bigger M&A themes (Optum carveout, CVS strategic review, Humana Medicaid sale).

Next catalysts: the September 30 New York-Presbyterian / UnitedHealthcare contract deadline; the CMS 2027 OPPS final rule (expected in the coming weeks) and the finalized state-directed-payment rule; Medicare Annual Enrollment (AEP) opening October 15; the October 1 Medicaid immigrant-eligibility change and the January work-requirement/redetermination cliff; and any Q3'26 pre-announcements.